Page 176 - 2022_02-Haematologica-web

E.-J. Choi et al.
mutations and high-risk disease. Am J
Hematol. 2019;94(7):757-766.
11. Sébert M, Passet M, Raimbault A, et al.
Germline DDX41 mutations define a signif- icant entity within adult MDS/AML patients. Blood. 2019;134(17):1441-1444.
12. Linder P. Dead-box proteins: a family affair- -active and passive players in RNP-remodel- ing. Nucleic Acids Res. 2006;34(15):4168- 4180.
13. DiNardo CD, Routbort MJ, Bannon SA, et al. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018;124(13):2704-2713.
14. Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing panels fre- quently identify germ line variants associat- ed with hereditary hematopoietic malignan- cies. Blood Adv. 2018;2(2):146-150.
15. Guidugli L, Johnson AK, Alkorta-Aranburu G, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syn- drome/acute leukemia predisposition syn- dromes. Leukemia. 2017;31(5):1226-1229.
16.Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syn- dromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
17. NCC Network. Myelodysplastic syndrome (Version 2.2020). https://www.nccn.org/ professionals/physician_gls/PDF/mds.pdf Accessed May 10, 2020.
18. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recom- mendation of the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet
Med. 2015;17(5):405-423.
19. Padron E, Ball MC, Teer JK, et al. Germ line
tissues for optimal detection of somatic vari- ants in myelodysplastic syndromes. Blood. 2018;131(21):2402-2405.
20. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring sys- tem for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
21. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129 (4):424-447.
22. Takeda J, Yoshida K, Makishima H, et al. Genetic predispositions to sporadic myeloid neoplasms caused by germline DDX41 mutations in Asian and Caucasian popula- tions. Haematologica. 2016; 101 (s1):66-67.
23. Polprasert C, Takeda J, Niparuck P, et al. Novel DDX41 variants in Thai patients with myeloid neoplasms. Int J Hematol. 2020;111(2):241-246.
24. Omura H, Oikawa D, Nakane T, et al. Structural and functional analysis of DDX41: a bispecific immune receptor for DNA and cyclic dinucleotide. Sci Rep. 2016;6(1):1-11.
25. Jiang Y, Zhu Y, Liu Z-J, Ouyang S. The emerging roles of the DDX41 protein in immunity and diseases. Protein Cell. 2017; 8(2):83-89.
26. Crawford J, Lower KM, Hennekam RC, et al. Mutation screening in Börjeson- Forssman-Lehmann syndrome: identifica- tion of a novel de novo PHF6 mutation in a female patient. J Med Genet. 2006; 43(3):238-243.
27. Ernst A, Le VQ, Højland AT, et al. The PHF6 mutation c. 1A> G; PM1V causes Börjeson-
Forsman-Lehmann syndrome in a family with four affected young boys. Mol Syndromol. 2015;6(4):181-186.
28. Todd MA, Ivanochko D, Picketts DJ. PHF6 degrees of separation: the multifaceted roles of a chromatin adaptor protein. Genes. 2015;6(2):325-352.
29. Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematolog- ical malignancies. Int J Hematol. 2017; 106(2):189-195.
30. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
31. Kobayashi S, Kobayashi A, Osawa Y, et al. Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoi- etic stem cell transplantation. Leukemia. 2017;31(4):1020.
32. Berger G, van den Berg E, Sikkema-Raddatz B, et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia. 2017;31(2): 520.
33. Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing panels fre- quently identify germ line variants associat- ed with hereditary hematopoietic malignan- cies. Blood Adv. 2018;2(2):146-150.
34. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 V617F-positive myeloproliferative neo- plasms. Nat Genet. 2009;41(4):455-459.
35. Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline tran- scription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136(1):24-35.
518
haematologica | 2022; 107(2)